NY‐ESO ‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO ‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO ‐1 fowlpox virus
Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: International Journal of Cancer
DOI: 10.1002/ijc.29118
Authors: Ji‐Li Chen, Amina Dawoodji, Andrea Tarlton, Sacha Gnjatic, Abdelouahid Tajar, Ioannis Karydis, Judy Browning, Sarah Pratap, Christian Verfaille, Ralph R. Venhaus, Linda Pan, Douglas G. Altman, Jonathan S. Cebon, Lloyd L. Old, Paul Nathan, Christian Ottensmeier, Mark Middleton, Vincenzo Cerundolo
Institutions: University of Oxford, MRC Weatherall Institute of Molecular Medicine, MRC Human Immunology Unit, Ludwig Cancer Research, Ludwig Cancer Research, Olivia Newton-John Cancer Wellness & Research Centre, Austin Health, Mount Vernon Hospital, Mount Vernon Cancer Centre, University Hospital Southampton NHS Foundation Trust, NIHR CRUK Experimental Cancer Medicine Centre, Churchill Hospital
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2116487491